-
I had an opportunity today to try my hands at protein folding on Surface. The snapshots were taken with my cellphone so the quality here may not be the best, but just a few pictures of hands on research methodologies. I have posted on this topic a few times but thought I would add a few pictures...
-
An interesting story on what a DNA report can reveal, in this case the woman has an X and a Y, instead of two Xs, like most females. It is somewhat rare but does exist with having internal testicles, and this produces extra high levels of estrogen, the the testosterone produced pretty much can't...
-
After all the recent news about the PSA test, here's a genomics answer. The MD Anderson Cancer Center, demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells. The new prostate cancer test will be performed at Clarient's Clinical...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-07-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Other Items of Interest, personalized medicine, DNA, Genomics, Prostate Cancer, Pharmacogenomics, PSA, Cancer Test
-
The software offers both detailed, localized views of genomic data, and a whole genome view, in a format somewhat similar to the way Google presents items on the web. It is free to download and use. There are also some sample data files available. I like the idea of the heat map view...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-06-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Other Items of Interest, DNA, Genomics, Research, Pharmacogenomics, MIT, Biomed, Broad Institute, Harvard
-
The program uses just plain old Java, but add this technology with sequencing information and with the 4D applications, studies can be virtually conducted to see how a medication would react with selected settings. Its resolution is scaleable to 100,000,000 pixels and more by using more than one...
-
This is good, a genomics test that can give some preliminary results on whether or not statins will have an adverse effect before prescribing them. As the post states here, this is something that could certainly use some marketing to physicians. Zocor at 40 mg is a very common dosage and...
-
Not too many years ago I remembered hearing the term “hospitalist” and asked what’s that? The hospitalist has evolved and is now one of the top growing professions. With Pharmacogenomics, we might be on the verge of a new specialty, a “Longevity Doctor”. We already have a dwindling...
-
Yesterday I posted about Bank of American hiring more research analysts in the area of healthcare investing and and also stated that Blogs are now becoming part of the research process , I have found several who read this blog. This page relates back to a a post about the commitment of the DeCode...
-
Pfizer is wasting no time to get the calculations running and numbers rolling. To stay in the market, they are attempting to find out as much as they can about potential side effects and other perhaps adverse affects of their drugs. Better than they find up them front, as it will make for better...
-
Intel and other venture capitalists seem to like the genomics business too. Personalized medicine holds the key to many areas of Pharmacogenomics and where healthcare is headed. Genomic sequencing stands to unlock many areas of information that will lead us to which drugs and combinations...
-
We all recently heard about the warning letters sent from the state of California to firms selling online personal DNA sequencing over the Internet, and requiring a physician’s prescription for the service. One company DeCode, has taken the letter to heart and is revising their marketing plant...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
07-12-2008
Filed under:
Filed under: Medically Related, Insurance, Pharma/FDA News, personalized medicine, DNA, Genomics, Sequence, Pharmacogenomics, Diagnostics, CPT, DeCode
-
What can happen with clinical trials, the death of one participant, which has not been fully determined as to whether or not the drug was the cause, puts a halt to the study. Something to keep in mind when considering volunteering for a study, there are no guarantees here. This also makes...
-
When will it start paying the bills? The science and development is somewhat fragmented like the rest of health care, and this is not to say in any way that phenomenal breakthroughs are not occurring by any means as they are. Part of the problem is having enough data, real time data for one...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
07-03-2008
Filed under:
Filed under: Medically Related, Technology, Insurance, My Commentaries, Physician, personalized medicine, DNA, Genomics, healthcare, Science, Pharmacogenomics